Aravindhan Veerapandiyan

1.3k total citations
72 papers, 775 citations indexed

About

Aravindhan Veerapandiyan is a scholar working on Molecular Biology, Genetics and Cellular and Molecular Neuroscience. According to data from OpenAlex, Aravindhan Veerapandiyan has authored 72 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 18 papers in Genetics and 13 papers in Cellular and Molecular Neuroscience. Recurrent topics in Aravindhan Veerapandiyan's work include Muscle Physiology and Disorders (17 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Hereditary Neurological Disorders (7 papers). Aravindhan Veerapandiyan is often cited by papers focused on Muscle Physiology and Disorders (17 papers), Neurogenetic and Muscular Disorders Research (16 papers) and Hereditary Neurological Disorders (7 papers). Aravindhan Veerapandiyan collaborates with scholars based in United States, United Kingdom and Switzerland. Aravindhan Veerapandiyan's co-authors include Julie Parsons, Mohamad A. Mikati, Vandana Shashi, Kelly Schoch, Emma Ciafaloni, William B. Gallentine, Cara L. Mack, Katy Eichinger, Cullen M. Dutmer and Edward C. Smith and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Biological Psychiatry.

In The Last Decade

Aravindhan Veerapandiyan

59 papers receiving 756 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aravindhan Veerapandiyan United States 16 389 244 178 163 111 72 775
M.V. Padma India 19 280 0.7× 189 0.8× 90 0.5× 72 0.4× 156 1.4× 59 1.1k
Élida Vázquez Spain 18 154 0.4× 74 0.3× 185 1.0× 44 0.3× 162 1.5× 49 968
Meral Özmen Türkiye 17 148 0.4× 40 0.2× 91 0.5× 109 0.7× 120 1.1× 67 830
Akira Sudo Japan 14 307 0.8× 57 0.2× 37 0.2× 79 0.5× 61 0.5× 35 685
Tatsuro Izumi Japan 16 225 0.6× 35 0.1× 184 1.0× 97 0.6× 71 0.6× 70 895
Gustavo Soto‐Ares France 15 108 0.3× 69 0.3× 78 0.4× 46 0.3× 202 1.8× 27 723
Roshan Koul Oman 15 165 0.4× 85 0.3× 39 0.2× 67 0.4× 181 1.6× 83 864
Dimitri Renard France 18 238 0.6× 62 0.3× 81 0.5× 36 0.2× 519 4.7× 147 1.1k
Abdelkarim A. Al-Qudah Jordan 12 147 0.4× 54 0.2× 88 0.5× 32 0.2× 79 0.7× 40 454
Reinier A. Mullaart Netherlands 14 201 0.5× 37 0.2× 115 0.6× 67 0.4× 28 0.3× 30 662

Countries citing papers authored by Aravindhan Veerapandiyan

Since Specialization
Citations

This map shows the geographic impact of Aravindhan Veerapandiyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aravindhan Veerapandiyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aravindhan Veerapandiyan more than expected).

Fields of papers citing papers by Aravindhan Veerapandiyan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aravindhan Veerapandiyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aravindhan Veerapandiyan. The network helps show where Aravindhan Veerapandiyan may publish in the future.

Co-authorship network of co-authors of Aravindhan Veerapandiyan

This figure shows the co-authorship network connecting the top 25 collaborators of Aravindhan Veerapandiyan. A scholar is included among the top collaborators of Aravindhan Veerapandiyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aravindhan Veerapandiyan. Aravindhan Veerapandiyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Chan, Kee, Jennifer Taylor, Bo Hoon Lee, et al.. (2024). Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening. International Journal of Neonatal Screening. 10(2). 34–34.
4.
Zaidman, Craig M., Amal Aqul, Russell J. Butterfield, et al.. (2024). Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 11(3). 687–699. 9 indexed citations
5.
Schroth, Mary, J. Deans, W. Bryan Burnette, et al.. (2024). Spinal Muscular Atrophy Update in Best Practices. Neurology Clinical Practice. 15(1). e200374–e200374. 5 indexed citations
6.
Neumann, Silke, W. Bryan Burnette, Rachel T. Cox, et al.. (2024). Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin. Pediatric Neurology. 163. 1–3. 2 indexed citations
7.
Kaufman, Beth D., Aravindhan Veerapandiyan, Jonathan H. Soslow, et al.. (2024). Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance. Journal of Neuromuscular Diseases. 12(2). 173–182. 2 indexed citations
8.
Wald, Ellen R., Jens C. Eickhoff, Michael V. Heinz, et al.. (2023). Estimate of the incidence of PANDAS and PANS in 3 primary care populations. Frontiers in Pediatrics. 11. 1170379–1170379. 3 indexed citations
9.
Kwon, Jennifer M., Kapil Arya, Nancy L. Kuntz, et al.. (2022). An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy. Annals of Clinical and Translational Neurology. 9(6). 810–818. 26 indexed citations
10.
Gill, Pritmohinder S., et al.. (2021). Molecular Dysregulation in Autism Spectrum Disorder. Journal of Personalized Medicine. 11(9). 848–848. 12 indexed citations
11.
Clouser, Katharine N., et al.. (2021). COVID-19 in Pediatric Inpatients: A Multi-Center Observational Study of Factors Associated with Negative Short-Term Outcomes. Children. 8(11). 951–951. 3 indexed citations
12.
Arya, Kapil, et al.. (2020). Combination therapy with nusinersen and AVXS-101: a real-world clinical experience (4152). Neurology. 94(15_supplement). 2 indexed citations
13.
Veerapandiyan, Aravindhan, Kathryn R. Wagner, Susan Apkon, et al.. (2020). The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic. Muscle & Nerve. 62(1). 41–45. 50 indexed citations
14.
Veerapandiyan, Aravindhan, et al.. (2019). Intrathecal nusinersen in older children and adults with spinal muscular atrophy (S5.001). Neurology. 92(15_supplement). 2 indexed citations
15.
Veerapandiyan, Aravindhan, Katy Eichinger, Érin Collins, et al.. (2018). Cervical Puncture to Deliver Nusinersen in Patients with Spinal Muscular Atrophy and no Lumbar Access (P2.333). Neurology. 90(15_supplement). 2 indexed citations
16.
17.
Veerapandiyan, Aravindhan, et al.. (2014). STUDY ON DRUG UTILIZATION PATTERN OF CHRONIC RENAL FAILURE PATIENTS IN A TERTIARY CARE HOSPITAL. International Journal of Pharmacy and Pharmaceutical Sciences. 6(9). 482–484. 5 indexed citations
18.
Veerapandiyan, Aravindhan, Omar Abdul‐Rahman, Margaret P Adam, et al.. (2011). Chromosome 22q11.2 deletion syndrome in African‐American patients: A diagnostic challenge. American Journal of Medical Genetics Part A. 155(9). 2186–2195. 18 indexed citations
19.
Veerapandiyan, Aravindhan, William B. Gallentine, Edward C. Smith, et al.. (2011). Electroencephalographic and seizure manifestations of pyridoxal 5′-phosphate-dependent epilepsy. Epilepsy & Behavior. 20(3). 494–501. 29 indexed citations
20.
Veerapandiyan, Aravindhan, et al.. (2011). Oculogyric crises secondary to lamotrigine overdosage. Epilepsia. 52(3). e4–e6. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.V. Padma Breakdown of academic impact, for papers by Élida Vázquez Breakdown of academic impact, for papers by Meral Özmen Breakdown of academic impact, for papers by Akira Sudo Breakdown of academic impact, for papers by Tatsuro Izumi Breakdown of academic impact, for papers by Gustavo Soto‐Ares Breakdown of academic impact, for papers by Roshan Koul Breakdown of academic impact, for papers by Dimitri Renard Breakdown of academic impact, for papers by Abdelkarim A. Al-Qudah Breakdown of academic impact, for papers by Reinier A. Mullaart
Rankless by CCL
2026